In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

GSK teams up with Epizyme on histone methyltransferase targets

Executive Summary

Epizyme Inc. (cancer treatments targeting epigenetic enzymes) has licensed GlaxoSmithKline PLC global rights to develop and sell small molecules against histone methyltransferases (HMT) for cancer and potentially additional indications.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register